Discontinued — last reported Q3 '23
CRCL Equity Method Investments increased by 14.3% to $96.36M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.7%, from $69.96M to $96.36M. Over 2 years (FY 2023 to FY 2025), Equity Method Investments shows an upward trend with a 13.0% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $66.01M | $70.82M | $69.86M | $68.23M | $69.96M | $76.04M | $74.93M | $84.27M | $96.36M |
| QoQ Change | — | +7.3% | -1.4% | -2.3% | +2.5% | +8.7% | -1.5% | +12.5% | +14.3% |
| YoY Change | — | — | — | +3.4% | — | +7.4% | +7.3% | +23.5% | +37.7% |